Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.10
Bid: 22.20
Ask: 25.40
Change: 0.00 (0.00%)
Spread: 3.20 (14.414%)
Open: 24.10
High: 0.00
Low: 0.00
Prev. Close: 24.10
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

26 May 2022 09:57

RNS Number : 9251M
Oncimmune Holdings PLC
26 May 2022
 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Oncimmune Holdings PLC

GB00BYQ94H38

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii: UBS trading book holdings in Oncimmune Holdings PLC fell below 5% and are therefore exempt from reporting

X

3. Details of person subject to the notification obligation iv

Name

UBS Investment Bank

UBS Group AG

City and country of registered office (if applicable)

Zürich

Switzerland

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

24 May 2022

6. Date on which issuer notified (DD/MM/YYYY):

26 May 2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

Below 5%

Below 5%

Below 5%

Below 5%

Position of previous notification (if

applicable)

5.398896%

0.000000%

5.398896%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYQ94H38

Below 5%

Below 5%

SUBTOTAL 8. A

0

Below 5%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

UBS Group AG

UBS AG

UBS AG London Branch

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

UBS trading book holdings in Oncimmune Holdings PLC fell below 5% and are therefore exempt from reporting

 

Place of completion

Zurich, Switzerland

Date of completion

26.05.2022

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLAFMPTMTATMTT
Date   Source Headline
25th Oct 20214:35 pmRNSPrice Monitoring Extension
25th Oct 20217:00 amRNSNotice of Full Year results
20th Sep 20217:00 amRNSAgreement with pharma company to profile patients
15th Sep 202111:08 amRNSBlock Listing Six Monthly Return
23rd Aug 20217:00 amRNSThree-year follow-up data for the ECLS trial
23rd Jul 20217:00 amRNSAgreement signed with major cancer center
22nd Jul 20217:00 amRNSValidation of ImmunoINSIGHTS service in COVID-19
1st Jul 20217:00 amRNSTotal Voting Rights
8th Jun 20217:00 amRNSFull Year Trading Update
28th May 20217:30 amRNSNotice of FY21 Trading Update
5th May 20217:03 amRNSReturn of China Rights to EarlyCDT
4th May 202112:23 pmRNSTotal Voting Rights
8th Apr 20217:00 amRNSHolding(s) in Company
7th Apr 20212:05 pmRNSSecond Price Monitoring Extn
7th Apr 20212:00 pmRNSPrice Monitoring Extension
6th Apr 20211:48 pmRNSBlock Listing Six Monthly Return
6th Apr 20217:00 amRNSAgreements signed with Roche and Cedars-Sinai
6th Apr 20217:00 amRNSHolding(s) in Company
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20212:01 pmRNSResult of Oversubscribed Equity Placing
25th Mar 20217:45 amRNSLaunch of Equity Placing via Accelerated Bookbuild
15th Mar 20217:00 amRNSIssue of Equity and Total Voting Rights
1st Mar 20217:00 amRNSTotal Voting Rights
15th Feb 20217:00 amRNSInterim Results
25th Jan 20217:00 amRNSNotice of Half Year Results
19th Jan 20214:17 pmRNSDirectorate Change
18th Jan 202111:37 amRNSHolding(s) in Company
14th Jan 20219:49 amRNSPDMR Dealing
6th Jan 202110:27 amRNSTotal Voting Rights
18th Dec 20207:00 amRNSPDMR Dealing
15th Dec 20207:00 amRNSAutoantibody profiles publication for RA treatment
14th Dec 20207:00 amRNSEarlyCDT Lung blood test launch into the NHS
30th Nov 202011:21 amRNSResults of Annual General Meeting
11th Nov 20207:00 amRNSAgreement with Augmenta Bioworks
9th Nov 20207:00 amRNSNotice of AGM and Posting of Annual Report
30th Oct 20207:00 amRNSFull year results and progress update
28th Oct 20207:00 amRNSClinical study initiated by Biodesix in US
21st Oct 20207:00 amRNSAbstracts of Studies using EarlyCDT Lung
19th Oct 20208:21 amRNSReplacement: Notice of Full Year Results
19th Oct 20207:00 amRNSNotice of Full Year Results ended 31 May 2020
13th Oct 20207:00 amRNSAgreement with Cedars-Sinai to Profile COVID-19
8th Oct 202011:05 amRNSSecond Price Monitoring Extn
8th Oct 202011:00 amRNSPrice Monitoring Extension
6th Oct 20207:00 amRNSUK Government funding for tool for use in COVID-19
23rd Sep 20207:00 amRNSProfiling samples from Genentech
15th Sep 20202:00 pmRNSBlock Admission
11th Sep 202012:14 pmRNSNew Incentivisation Scheme for Senior Management
3rd Sep 20207:00 amRNSCost-effectiveness study assessing EarlyCDT Lung
2nd Sep 20207:00 amRNSAutoantibody profiling agreement signed
13th Aug 202011:38 amRNSExercise of Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.